Skip to content
Screener

Insmed INSM Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$5.33M-103%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%
Savara logo
SavaraSVRA
-$40.33M-34.5%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$43.6M+32.1%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
-$39.93M+0.4%
Rein Therapeutics Inc. logo
Rein Therapeutics Inc.RNTX
-$5.84M-5.9%

Other financials

Income statement

See full
Revenue$425.5M+296%
Gross profit$358.3M+352%
Operating income-$1.5M+99.5%
Net income-$13.2M+95.9%
EPS (diluted)-$0.06+96.5%

Balance sheet

See full
Cash & equivalents$544.8M-57.6%
Total debt$579.9M+0.8%
Total equity$757.5M-39.4%
Total assets$2.1B-15.2%

Cash flow

See full
Operating cash flow-$88.8M+56.8%
CapEx$6.3M+79.6%
Free cash flow-$95.1M+54.5%

Valuation

See full
Market cap$28.63B+20.0%
Enterprise value$28.66B+23.8%
P/S25.2×-34.8×

Profitability

See full
Gross margin83.5%+7.7pp
Operating margin-73.9%-30.6pp
Net margin-76.9%-31.8pp
FCF margin-71%-28.6pp

Returns & leverage

See full
Return on equity-87.2%-27.3pp
Debt / equity0.8×+0.3×
Current ratio3.7×-3.0×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Insmed’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104506-26-000041
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss$(13,242)$(321,686)$(176,805)$(578,269)
Basic and diluted net loss per share$(0.06)$(1.70)$(0.82)$(3.12)
Weighted average basic and diluted common shares outstanding217,352189,302216,415185,104
Net loss$(13,242)$(321,686)$(176,805)$(578,269)
Other comprehensive income (loss):
Foreign currency translation (losses) gains(2,906)2,656(3,574)4,484
Unrealized loss on marketable securities(471)(22)(1,260)(463)
Total comprehensive loss$(16,619)$(319,052)$(181,639)$(574,248)

Item 1C. Consolidated Financial Statements

FAQ

What is Insmed's comprehensive income (loss), net of tax, attributable to parent?
Insmed (INSM) reported comprehensive income (loss), net of tax, attributable to parent of -$16.62M in Q2 2026.
How has Insmed's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Insmed's comprehensive income (loss), net of tax, attributable to parent increased by 94.8% year-over-year, from -$319.05M to -$16.62M.
What is the long-term trend for Insmed's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Insmed's comprehensive income (loss), net of tax, attributable to parent has grown at a 30.9% compound annual growth rate (CAGR), from -$433.88M to -$1.27B.
What does comprehensive income (loss), net of tax, attributable to parent mean?
The total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It provides a broader view of financial performance than net income alone by including unrealized gains and losses.

Ask your AI about Insmed's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude